[ad_1]
The coronavirus infection vaccine, developed by Johnson & Johnson, was approved for emergency use in the United States on Saturday, bringing the arsenal of vaccines to fight the COVID-19 pandemic, which claimed more than $ 500,000. American life has been supplemented with another simpler tool.
This vaccine is the third nationally approved vaccine against COVID-19. It is considered an inexpensive alternative to Pfizer and Moderna vaccines and can also be stored in the refrigerator instead of the freezer.
Clinical trials of the vaccine in the United States, South Africa, and Brazil have shown it to be extremely effective, with over 85% preventing the severe form of COVID-19 and including the moderate efficacy of the vaccine at 66%.
The company agreed to deliver 100 million to the country at the end of June. vaccine dose. The first doses can be given starting next week. The vaccine is manufactured by the Belgian pharmaceutical company Janssen, owned by Johnson & Johnson.
Approval of the third vaccine is considered vital in the US as the country seeks to accelerate vaccination rates.
“This is good news for all Americans and an encouraging boost in our efforts to end this crisis,” said US President Joe Biden.
However, he urged Americans to remain vigilant and adhere to restrictions imposed by the virus, such as social distancing requirements, and warned that new strains of the virus remain a threat.
“But we cannot relax now or think that victory is inevitable,” he said.
The vaccine developed by Johnson & Johnson is already the third COVID-19 vaccine certified for distribution in the United States.
It is seen as a crucial move to further accelerate the vaccination campaign in the United States, where the coronavirus infection has claimed more than 500,000 lives. human lives.
In large clinical trials, the effectiveness of the Johnson & Johnson vaccine in preventing severe COVID-19 was 85.9%. In the United States, 81.7 percent. In South Africa and 87.6 percent. In Brazil.
In all the mentioned regions, 39,321 thousand people participated in the research. in humans and the overall efficacy of the vaccine in preventing a severe form of infection was 85.4 percent, but, including milder forms of the disease, it was less than 66.1 percent.
However, it is important to note that the analysis of different demographic groups did not reveal significant differences in efficacy in terms of age, race or people with comorbidities.
The United Kingdom (UK), the European Union (EU) and Canada have also ordered doses of this vaccine, with another 500 million. Doses were ordered under the Covax schedule to ensure that vaccines were available to poor countries.
To date, about 72.8 million have been vaccinated in the United States. people. President Joe Biden has promised that 100 million will be vaccinated in the first 100 days of his presidency. people.
In total, more than 508 thousand people died from the effects of the infection in the country. people. The number of new infections, hospitalizations and deaths has been declining in recent weeks.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
